Short Summary
Nexus Pharmaceuticals' PGR challenge against Exela Pharma Sciences was denied institution because the arguments regarding enablement, written description, and obviousness were largely identical to those previously presented during prosecution. The Board found that the Patent Owner successfully demonstrated how process controls overcome prior rejections, leading to a denial of the petition under § 325(d).
Detailed Summary
Nexus Pharmaceuticals LLC challenged claims 1-30 of Exela Pharma Sciences' patent (No. 11642370) on grounds including lack of enablement, written description, and obviousness. The Patent Owner successfully argued that the petition should be denied institution under 35 U.S.C. § 325(d), asserting that similar arguments had already been presented to the Office during prior prosecution and earlier PGR proceedings. The Board agreed, finding that the Petitioner failed to demonstrate a material error because the Patent Owner had previously overcome enablement rejections by demonstrating control over variables like reduced oxygen and aluminum levels using processes taught in the specification. Consequently, the institution of the petition was denied.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Nexus Pharmaceuticals LLC vs Exela Pharma Sciences, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Advanced Micro Devices, Inc. et al.vsXtreamEdge, Inc. et al.
Advanced Micro Devices (AMD) successfully petitioned to institute IPR proceedings against XtreamEdge regarding a PLD patent, demonstrating a reasonable likelihood of prevailing on key claims. The Board found that the combination of prior art references Seshadri and Biederman provided sufficient grounds for challenge under 35 U.S.C. § 103.
National Beef Packing Company, LLCvsInstitute for Environmental Health, Inc.
National Beef Packing Company challenges Patent 9845486 on grounds of anticipation and obviousness in microbiological detection methods. The Petitioner argues that prior art references, including Rayman and Nagar, disclose or render obvious the claimed steps involving sampling, dilution, and assaying.
Taiwan Semiconductor Manufacturing Company, Ltd.vsAdvanced Integrated Circuit Process LLC
TSMC has filed an IPR petition seeking cancellation of 27 claims of a dual‑damascene interconnect patent, alleging anticipation and obviousness over multiple prior‑art references. The petition lists detailed grounds for each claim group and requests the Board to institute the review.
Google LLCvsSecure Communication Technologies, LLC
Samsung and Secure Communication Technologies settled their IPR disputes, leading the Board to terminate the proceedings before any trial was instituted.
Advanced Micro Devices, Inc. et al.vsConcurrent Ventures, LLC et al.
AMD and Pensando’s IPR petition against the ’596 patent is challenged by Concurrent Ventures and XtreamEdge, who argue the petition fails to identify claim construction and does not show prior art meets the claimed hardware queue limitations, seeking a discretionary denial of institution.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.